Program
EC5026
Also written as “EC5026 oral tablet” and “EC5026 oral capsule”.
Its studies are mostly in Spinal Cord Injuries · Renal Insufficiency, Chronic, led by EicOsis Human Health.
Furthest: phase 2, since Aug 19, 20256 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| EicOsis Human Health | 63 open or running | phase 2since Aug 19, 2025 | Jan 6, 2020 | Dec 2026phase 2 · NCT07142044 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 6, 2020First study: phase 1 study in Healthy AdultsFirst studyNCT04228302 · 40 enrolled · United States
- May 26, 2021Phase 1 study in Healthy AdultsNCT04908995 · 18 enrolled · United States
- Oct 12, 2023Phase 1 study in Healthy SubjectsNCT06089837 · 16 enrolled · New Zealand
- May 24, 2024Phase 1 study in Spinal Cord InjuriesNCT06438471 · 36 planned · United States
- Aug 19, 2025Phase 2 study in Parkinson's Disease (PD)NCT07142044 · 18 planned · United States
- Jul 3, 2026Phase 1 study in Renal Insufficiency, ChronicNCT07694544 · 18 planned · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Parkinson's Disease (PD)NCT07142044
- Dec 31, 2026Primary completion: phase 1 study in Renal Insufficiency, ChronicNCT07694544
- Dec 2027Primary completion: phase 1 study in Spinal Cord InjuriesNCT06438471
TargetBeta
EPHX2 →read by rule
“The study drug, EC5026, is an orally bioavailable inhibitor of an enzyme, soluble epoxide hydrolase (sEH), that is being developed as a first-in-class anti-inflammatory agent.”study text, by rule · the study
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07694544Renal Insufficiency, Chronic · United States | 1 | Recruiting | Dec 31, 2026 | 18 |
| NCT07142044Parkinson's Disease (PD) · United States | 2 | Recruiting | Dec 2026 | 18 |
| NCT06438471Spinal Cord Injuries · United States | 1 | Recruiting | Dec 2027 | 36 |
| NCT06089837Healthy Subjects · New Zealand | 1 | Completed | Mar 13, 2024 | 16 |
| NCT04908995Healthy Adults · United States | 1 | Completed | May 12, 2021 | 18 |
| NCT04228302Healthy Adults · United States | 1 | Completed | Jul 7, 2020 | 40 |
How it is read
Names in the registry
- “EC5026 oral tablet”, 5 entries
- “EC5026 oral capsule”, 1 entry
Conditions, from the studies’ own filings
- Spinal Cord Injuries, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.